Pressure is mounting on pharmaceutical companies as drug development costs soar past $2.23 billion per drug for major firms, timelines extend over 10 to 15 years and nearly 90% of clinical trials end in failure. At the same time, the demand for faster, more affordable and effective therapies continues to grow. Artificial intelligence (AI) has emerged as a promising solution, with the potential to revolutionize the discovery, development and delivery of drugs to patients.
This webinar will explore how AI is being utilized to address today’s most significant opportunities and challenges in drug discovery and development, as well as where the field is headed in the future. Drawing on the latest data and expert insights, the speakers will assess how AI is performing relative to high expectations, what’s working and where improvements are still needed. This webinar will also dissect the competitive arena, covering key players from pharmaceutical giants to “TechBios,” as well as the mergers, acquisitions and collaborations that are defining the future.
This webinar will provide a clear-eyed view of where AI is delivering real value in drug development, where it still needs to prove itself and what to watch for next.
Speakers
Sara Mallatt, Director of Healthcare Research, AlphaSense
Sara has over 18 years of experience generating sell-side research content across various industries. Before joining AlphaSense, Sara held leadership positions at OTR Global, a leading channel research firm, most recently as Director of Healthcare Research. Sara earned a Bachelor’s degree in Journalism and a Master’s in Industrial Engineering.
Message Presenter
Dr. Paul Agapow, Former Director of Data Science, GSK
Originally an immunologist, Dr. Agapow was drawn to the intersection of the biomedical and computational sciences, bridging the knowledge and cultures of these two fields. Following stints in academia, frontline epidemiology and big pharma, Dr. Agapow now advises various companies on the pragmatic use of AI in biotech and drug development.
Message PresenterWho Should Attend?
This webinar will appeal to professionals in the following fields:
- Business development
- Analyst relations
- Competitive intelligence
- Corporate development
- Corporate strategy
- Investment
- Market intelligence
- Market insight
- Market research
- Mergers & acquisitions
- M&A
- Strategic planning
- Business operations
What You Will Learn
Attendees will gain insights into:
- Where the biggest opportunities lie for AI to make an impact in drug development, and what major challenges still remain
- How AI is performing vs. expectations, and whether early predictions (like AI discovering 30% of new drugs by 2025) are materializing
- How the competitive landscape is evolving, and where investment and consolidation might be headed
Xtalks Partner
AlphaSense
AlphaSense is the AI platform redefining market intelligence and workflow orchestration, trusted by thousands of leading organizations to drive faster, more confident decisions in business and finance. The platform combines domain specific AI with a vast content universe of over 500 million premium business documents — including equity research, earnings calls, expert interviews, filings, news, and internal proprietary content. Purpose-built for speed, accuracy, and enterprise-grade security, AlphaSense helps teams extract critical insights, uncover market-moving trends, and automate complex workflows with high quality outputs. With AI solutions like Generative Search, Generative Grid, and Deep Research, AlphaSense delivers the clarity and depth professionals need to navigate complexity and obtain accurate, real-time information quickly. For more information, visit www.alpha-sense.com.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account